Expert insight 2 May 2023

The power of partnerships and innovation: Accelerating progress toward Universal Health Coverage by 2030

In a blog for PharmaBoardroom, Thomas Cueni shares his views on the innovative pharmaceutical industry’s role in bringing critical solutions to accelerate progress toward UHC, from lab to the last mile.

Read more
Expert insight 28 Apr 2023

Progress in tackling antimicrobial resistance

Since antibiotics were discovered nearly a century ago, the rate of resistance growth is outpacing the rate at which new ones can be developed and be used against infections. If we lose this race, patient deaths will significantly increase from the current 1.2 million per year. The pharmaceutical industry recognized the impending crisis and set...

Read more
Statement 27 Apr 2023

Open letter to G20 Ministers in support of the advancement of the G20 Health Agenda

On 27 April 2023, IFPMA and OPPI issued an open letter to Health Ministers of the G20, highlighting the innovative pharmaceutical industry support for G20 health priorities.

Read more
Expert insight 26 Apr 2023

Why confidence in vaccines matters today and in the future?

During the pandemic, vaccines were at the top of the news agenda and at the forefront of people’s minds like never before. Scientists were celebrated on magazine covers, and vaccine makers became household names. The largest vaccination campaign in history helped to save millions of lives, protecting people from serious illness and helping our world...

Read more
Statement 24 Apr 2023

24th WHO Expert Committee Meeting on the Selection and Use of Essential Medicines

On 24 April, IFPMA delivered a statement at the 24th WHO Expert Committee Meeting on the Selection and Use of Essential Medicines, held from 24-28 April 2023. 

Read more
Position paper 21 Apr 2023

Reinforcing collaboration on Universal Health Coverage to deliver greater global health equity and health security

The innovative pharmaceutical industry stands together with other members of the global health community to support countries in accelerating their efforts to achieve UHC. Read our position paper.

Read more
Expert insight 19 Apr 2023

Why vaccines and continued vaccine innovation matter today and for the future?

Every year during World Immunization Week we take the time to celebrate the impact of vaccines, but this year there is heightened concern and apprehension around the status of vaccination programs around the world. The big catch-up year Recent pandemic disruptions to health and education systems have led to significant drops in childhood vaccination numbers,...

Read more
Statement 17 Apr 2023

Third meeting of the Working Group on Amendments to the International Health Regulations (2005)

On 17 April, IFPMA delivered a statement at the third meeting of the Working Group on Amendments to the International Health Regulations (2005) held from 17-20 April 2023.

Read more
Press release 14 Apr 2023

Top pharma leaders meet with Japanese officials to discuss G7 global health priorities and strategic dialogue for life science growth in Japan

CEOs met with Japanese Prime Minister Fumio Kishida and other officials in Japan, presenting the Tokyo Statement, which outlined top priorities for addressing global health challenges. They also discussed the importance to strengthen the innovation ecosystem in Japan and proposed establishing a strategic dialogue platform to enhance Japan's leadership position in the life science sector by fostering innovation that benefits both patients and economic growth.

Read more
Position paper 12 Apr 2023

Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List

The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.

Read more
Position paper 5 Apr 2023

Registration of multiple manufacturing sites in one product license

In a joint position paper, EFPIA, IFPMA and Vaccines Europe urge all countries to adopt a ‘multiple-site-to-one-license’ approach for registrations, in line with WHO and other guidelines. This will result in a reduction of duplicate work for all stakeholders, help to build agility and speed in supply chain management and improve patient access to medicines and vaccines.

Read more
Expert insight 3 Apr 2023

How do we forge a shared path toward universal health coverage in Africa?

This month, I had the priviledge to return to Kigali, Rwanda after the launch of the State of UHC in Africa Report to witness next steps toward the delivery of health services for all. Since the report’s launch in 2021, Amref Health Africa has been working behind the scenes to develop the UHC Delivery Lab....

Read more